Purpose: Whether the progression of advanced pancreatic ductal adenocarcinoma (PDAC) patients could be affected by HBV exposure remains to be determined. Therefore, we conducted this study to assess the effect of HBV infection on PDAC progression among a large cohort in China.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the United States and the seventh leading cause of cancer deaths in China [1, 2] . Due to the obscure symptoms at early stages and the aggressive progression of the disease, only around 15-20% of PDAC patients have a chance to receive radical surgery at diagnosis and most of the patients are detected the disease with unresectable advanced tumors [3] . Due to the limited options for patients with PDAC at locally advanced and metastatic stages, these patients with unresectable PDAC often have dismal prognosis. Mounting evidences have demonstrated that some clinical parameters may affect the survival of PDAC patients such as tumor stages, postoperative pathological findings and CA-199 level [4] [5] [6] . However, to date whether hepatitis B virus (HBV) infection could influence the prognosis in patients with advanced PDAC has not been well established and confirmed yet.
China is one of the countries boasting high endemicity of HBV infection [7] . Roughly 7.2% of the Chinese population are chronic HBsAg carriers and approximately 60% have been exposed to HBV infection [ 8] . Thus, there is a great likelihood that some PDAC patients are also HBsAg carriers or they once were subject to HBV exposure. HBV is a well-known oncogenic virus for hepatocellular carcinoma (HCC) [ 9] , which may also cause some extrahepatic malignancies or diseases, such as non-Hodgkin lymphoma [10, 11] , aplastic anemia [12] and nephritis [13] . The presence of HBV infection in extrahepatic sites such as pancreas and other organs has been identified in multiple studies [14] [15] [16] .
Recently, opinions abound on whether there is an association between HBV infection and risk of PDAC but with no consistent conclusion has been reached on this issue [17] [18] [19] . Some studies have demonstrated that HBV infection may decrease the risk of liver metastasis in colorectal cancer (CRC) [20, 21] . Some studies showed that CRC patients with HBV infection may survive longer than those without [22, 23] . Whether the prognosis of advanced PDAC could be affected by HBV exposure remains to be determined, the result of which would be of great significance for future clinical practice. Herein, we conducted this multicenter cohort study to explore whether liver metastasis and survival in locally advanced and metastatic PDAC could be affected by HBV infection.
PATIENTS AND METHODS

Study populations
From January 1, 2004, to December 31, 2013, we conducted a multicenter cohort of patients with unresectable PDAC, including stage III and IV cases, at three participating hospitals, Shanghai Cancer Center(SCC), Changhai Hospital(CHH) and Ruijin Hospital(RJH). All the patients included were pathologically proved PDAC. In this study, data from 1526 patients with serologic assay for HBV infection in the cohort were finally analyzed.
This study was carried on in accordance with the precepts of the Helsinki Declaration. Approvals were obtained from the Human Investigations Committee at all the participating hospitals. During the hospital stay, every included patient or their guardians signed the informed consent in view of prospective research of the clinical data.
Exposure measurements HBV status
Upon the initial admission to the in-patient department, blood samples were obtained from every patient. Based on the positivity of five routine markers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb) and HBV-DNA levels, we categorized patients into four groups as following: patients with no infection, patients with chronic HBV infection, inactive HBV carriers and patients with resolved HBV infection. Patients with no infection were those with negative HBsAg and negative anti-HBc. Chronic hepatitis B was defined as being HBsAg and anti-HBc positive, and at least one of HBeAg positive and HBV DNA positive. Those with positive HBsAg positive, and both HBeAg and HBV-DNA negative were labeled as inactive HBsAg carriers. Patients with negative HBsAg while positive with either anti-HBe or anti-HBc were subject to resolved HBV infection [24, 25] .
Other parameters
Blood samples for measurement of serum CA199, liver function and serum amylase were obtained at the diagnosis. Medical records of smoking status and alcohol consumption of the patients were also reviewed.
carrier(IC) and resolved HBV infection showed no significant association with survival compared to non HBV infection.
Conclusion: This study indicated that CHB infection may serve as an independent factor which decrease synchronous or metachronous liver metastasis, and increase overall survival among advanced PDAC patients. www.impactjournals.com/oncotarget
Verification for clinical materials
All the cases were first reviewed by two doctors at each participating hospital, and then the clinical data was transferred to Shanghai Cancer Center. Two experienced doctors at Shanghai Cancer Center went through these clinical materials to determine the inclusion or the exclusion of the cases. If divergent views arise, a third doctor would be consulted for the final assessment of inclusion or exclusion.
Outcome ascertainment
Synchronous liver metastasis
Up to now, there has been no established definition for synchronous liver metastasis from PDAC. In this study, we defined synchronous liver metastasis as follows:
Synchronous liver metastasis is defined as the detection of liver metastasis at the initial diagnosis of PDAC. The PDAC should be pathologically confirmed and the liver metastasis should be validated by imaging examination, including ultrasound, CT, MRI and PET-CT scan.
Overall survival and metachronous liver metastasis
All the patients in this study underwent the regular follow-up evaluations. Survival condition was actively followed up every month. For deceased patients, dates of death were obtained from their family members via telephone if the patients died after discharge or were recorded immediately if the patients died during hospitalization. The follow-up ended after the obtainment of death date.
Imaging evaluations were performed every 2 months within the first 3 years and every 3 months thereafter, of which chest X-ray, abdominal ultrasonography, triphasic cross-sectional abdominal CT or MRI were included. The images were initially reviewed by an experienced radiologist at each participating hospital and then reevaluated by a radiologist at Shanghai Cancer Center. If inconsistent evaluation were reached by the first two doctors, a third radiology specialist at Shanghai Caner Center would be invited to give the conclusive evaluation.
Metachronous liver metastasis is defined as that liver metastasis can't be found via imaging examination at the initial diagnosis of PDAC while can only be found during the follow-up imaging examinations, regardless of the time after the initial diagnosis. For example, liver metastasis detected one month or twelve months after the initial diagnosis of PDAC were both considered as metachronous liver metastasis.
Statistical analysis
The statistical analyses were performed with SAS statistical software (version 9.4; SAS Institute). P values < 0.05 (two-sided probability) were interpreted as statistically significant.
Difference of synchronous liver metastasis rates between HBsAg positive and negative groups in stage IV patents were evaluated by chi-square test. A multivariate Logistic regression model was performed to analyze the association between HBV status and synchronous liver metastasis.
Crude metachronous liver metastasis rates of stage III patients were calculated based on the time interval from the date of diagnosis of pancreatic cancer to liver metastasis ascertained at follow-up stage, using the actuarial method that was usually performed in colorectal cancers [26] . Patients who died of undercurrent disease were censored at time of death, and patients who developed liver metastasis were censored at the time of occurrence. A multivariate analysis was performed using a Cox proportional hazards regression model to analyze the association between HBV status and metachronous liver metastasis.
Overall survival (OS) was the time interval from the date of diagnosis to death or to the last date of follow-up. OS curves were plotted with the Kaplan-Meier method, and differences between subgroups were evaluated by logrank test. Cox regression models were used for univariate and multivariate analyses.
RESULTS
Cohort characteristics
A total of 1526 cases (833 from SCC, 486 from CHH, and 207 from RJH) that consisted of 553 females (36.2%) and 973 males (63.8%) were qualified for the analyses. Mean age at diagnosis was 58.6 years. Patients of stage III and IV were 595 (39.0%) and 931 (61.0%), respectively.
Non HBV infection was identified in 833 patients (54.6%). CHB was identified in 61 patients (4.0%). Inactive HBV carrier was identified in 83 patients (5.4%), and resolved HBV infection was identified in 549 patients (36.0%). Thus, 144 (9.4%) patients were enrolled in HBsAg positive group (CHB +IC), and 1382 (81.6%) patients were classified into HBsAg negative group (resolved HBV infection + non HBV infection). Detailed baseline characteristics are listed in Table 1 . Proportions of CHB, IC, resolved HBV infection and non HBV infection are comparable between stage 3 and stage 4 patients, male and female patients, smoker and non-smoker patients, as well as alcohol and non-alcohol patients. www.impactjournals.com/oncotarget
Synchronous liver metastasis
Among stage IV patients, synchronous liver metastasis status were described at baseline. Synchronous liver metastasis was found in 810 (87%) patients. Synchronous liver metastasis rates in CHB, IC, resolved HBV infection and non HBV infection groups were 72.3%, 81.7%, 89.8% and 87.1%, respectively. Thus synchronous liver metastasis rates in HBsAg positive and negative groups were 77.6% and 88.3% (χ 2 = 9.51, P = 0.0020), respectively.
In multivariable Logistic regression adjusted for other confounders, CHB was inversely associated with synchronous liver metastasis compared to non HBV infection (OR 0.41, 95% CI 0.19-0.85). IC and Resolved HBV infection showed no significant association with synchronous liver metastasis compared to non HBV infection. Detailed univariate and multivariate analyses are listed in Table 2 .
Metachronous liver metastasis
Among 595 stage III patients, 186 (31.3%) developed a metachronous liver metastasis during follow up period after diagnosis. The overall actuarial cumulative rate was 6.2% at 3 months, 18.1% at 6 months, and 37.3% at 12 months. In different HBV status, 1 (7.1%) patent in CHB group, 4 (17.4%) in IC group, 64 (31.3%) in resolved HBV infection group and 117 (34.1%) in Non HBV infection group developed a (Table  3) . CHB (HR = 0.11, 95% CI 0.02-0.82) is considered as a protective factor of metachronous liver metastasis compared to Non HBV infection.
Overall survival
The total follow-up period of this study lasted ten years from 2004 to 2014.The median follow-up for all patients was 6.2 months (range, 0.4 to 98.1 months). During this period, 1362 patients (89%) died, and 164 patients (11%) were censored. The median survival of stage III patients was 9.0 months, with 3-, 6-and 12-month survival rates of 94.5%, 73.0% and 28.5% respectively. The median survival of stage IV patients was 5.3 months, with 3-, 6-and 12-month survival rates of 79.3%, 42.6% and15.0% respectively.
The survival curves of CHB vs. non HBV infection, IC vs. non HBV infection and resolved HBV infection vs. non HBV infection plotted with Kaplan-Meier method were shown in Figure 1 . The stage IV CHB patients had significantly longer overall survival than patients without HBV infection (P = 0.0243).
Association between HBV status and overall survival was analyzed in a multivariate Cox model adjusted for other covariables (Table 4) . For stage IV patients, CHB (HR = 0.70, 95% CI 0.51-0.95) is considered as a protective factor of overall survival compared to Non HBV infection.
DISCUSSION
Our study showed that patients with CHB had significant lower rate of liver metastasis compared with the non-HBV infection group, which indicated that HBV infection with active replication might serve as a protective factor for liver metastasis in PDAC. Additionally, the overall survival of patients in the stage IV CHB group is significantly longer than that in the non-HBV infection group, indicating the essential role of CHB in the outcome among PDAC patients and its prognostic indicator for overall survival among PDAC patients.
Some studies have demonstrated that the incidence of liver metastasis in colorectal cancer was lower in patients with HBV infection compared to the uninfected ones [20] [21] [22] [23] . Our study showed a similar trend in synchronous and metachronous liver metastasis in the unresectable PDAC. In the present study, CHB is associated with less metachronous liver metastasis in unresectable PDAC. To some extent, it even serve as a protective factor, extending the overall survival of these patients. However, Wei et al. [27] found that HBV infection increased synchronous liver metastasis incidence. Nevertheless, our study gave out a different answer to the synchronous liver metastasis regarding HBV status. Moreover, prevalence of metachronous liver metastases showed a similar tendency as that in synchronous metastases. The association between HBV and liver metastasis in our study is consistent with some previous reports in colorectal cancer while inconsistent with Wei's study. Notably, Wei's study enrolled both the operable and the non-operable subjects. Patients with HBV infection may receive surveillance ultrasound every 3-6 months as a means for detection of HCC at early stage. Since routine ultrasound performance can help detect PDAC at early stage, it is sensible that PDAC patients with HBV infection have better prognosis by means of operation due to early detection. Therefore, the underlying possibility can be a misleading factor affecting the outcome of OS in the patients at different cancer stages in the study led by Wei [27] . It has to be noted that the prognosis of patients undergoing surgery are more likely to be influenced by parameters like surgical margin, lymphatic metastasis and nerve invasion, as reported by numerous studies. Therefore, the current study only enrolled non-operable patients to exclude the unknown influences. To the best of our knowledge, our cohort study is the largest one centering on the effect of HBV infection in PDAC patients up to date.
It has been demonstrated that the existence of HBV virus in pancreatic juice, bile and tissue in patients with HBV positivity, which suggested HBV may be one of the major etiological factors for PDAC [14, 16] . Some studies suggested that the past exposure to HBV infection(resolved HBV infection) may enhance the risk of suffering from PDAC [17] , while some other studies suggested that HBV infection may not be a risk factor for the pathogenesis of PDAC [18, 19, 28] . Currently, whether HBV plays a prognostic role in the progression of advanced PDAC remains controversial and needs to be further explored. It has to be noted that this cohort study focused on the impact of current and previous exposure to HBV. Our study found that rather than a detrimental factor accelerating liver metastasis, HBV infection may act as a protective factor to hinder liver metastasis in patients with advanced PDAC. And these findings may contradict with HBV's carcinogenic role. Prior to this study, we conjectured that patients with current or past exposure to HBV infection maybe have poorer OS or higher incidence of liver metastasis as compared to their non-infected counterparts. However, our study may suggest that HBV may be a favorable prognostic factor for unresectable PDAC during its progression.
In addition, similar observation was also found in colorectal cancer. Song et al [22] found that the incidence of liver metastasis in the HBV infection group was significantly lower than that in the non-infection group. Therefore, we speculated that HBV may serve as a beneficial factor in PDAC patients, possibly by undermining the invasive and metastatic ability of the primary tumor. However, the underlying mechanisms remain to be explored.
As is generally recognized, long-term persistence of HBV infection can cause an inflammatory microenvironment in the liver [29] , which may trigger enhanced immune defense [30, 31] . The boosted immune responses were assumed to be beneficial in the inhibition of hepatic metastasis among PDAC patients [30, 31] . It has been reported that HBV replication can enhance the cytotoxic ability of a series of immune cells, the major players involving in the immune responses [32, 33] . These functional immune cells are featured by Kupffer cells, NK cells, NKT cells, dendritic cells and CD8+CD122+ [34, 35] . Metastases of hematogenous tumor to the liver can also be inhibited by NKT cells stimulated with recombinant interleukin-12 (IL-12) [36] . Meanwhile, tumor growth in the liver can be inhibited by α-GalCer, inductor of bystander CD8+ CD122+ T cells and tumorspecific cytotoxic CD8+ T cells [36, 37] . These cells altogether formed a niche in the liver of patients with CHB, rendering the liver not a proper site for metastasis.
In addition, HBV replication may boost tumor necrosis factor a (TNF-a) secretion via regulating hepatocytes and immune cells residing in the liver [38] . In view that HBV can also replicate in pancreas [14, 16] , we speculate that HBV also plays a role in the biological behavior of PDAC, thereby attenuating tumor invasiveness. Pitifully, there was no data reflecting the status of HBV infection in the pancreas or its immunity variation in this study. Therefore, further investigations are needed to explore the immunity microenvironment in pancreatic cancerous tissue in PDAC patients with CHB.
Despite increased survival in PDAC patients with the treatment of nab-Paclitaxel plus Gemcitabine [39] , the prognosis of advanced PDAC remains grim. Up to now, there have been no studies demonstrating the benefit of anti-viral medication in patients with CHB infection. Contrary to the conventional view, we assumed that CHB may be a protective factor for unresectable PDAC patients. Therefore, the anti-viral regimen may not be necessary for PDAC patients with CHB as it may even worsen the prognosis. Further rigorously designed clinical trials are needed to confirm our conjecture, which may provide new insights into the prevention of liver metastasis and prioritize the treatment strategy to extend PDAC patients' life expectancies.
LIMITATION OF THIS STUDY
It has been demonstrated that HBV exists in both cancerous tissue and noncancerous pancreatic tissue in PDAC patients. In this cohort, evidence suggests a link between HBV serum markers and the progression of advanced PDAC, but data directly reflecting the status of HBV infection in the pancreas or its immunity variation lacked. Further investigations are needed to explore the immunity microenvironment in pancreatic cancerous tissue in PDAC patients with CHB. This may help more directly understand the invasiveness of PDAC influenced by HBV infection. Meanwhile, CHB is not significantly associated with OS for stage III patients, which may be due to lacking of power. Thus, more participating centers and more subjects may be needed to confirm the protective role of CHB for stage III PDAC patients.
CONCLUSIONS
The present study demonstrated that CHB infection may decrease the risks of synchronous or metachronous liver metastasis, and prolong overall survival in advanced PDAC patients. However, more researches are warranted to investigate the underlying mechanisms involved. And whether anti-HBV medication could benefit advanced PDAC patients needs to be proven in future clinical trials.
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